Here's Why MannKind Corporation Stock Is Tanking Today [The Motley Fool]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: The Motley Fool
News that the biopharma lost more than expected in the first quarter sent shares into a tailspin. Brian Feroldi ( TMFTypeoh ) May 11, 2017 at 4:09PM What happened Following the release of the company's first-quarter earnings results, shares of MannKind ( NASDAQ:MNKD ) , a commercial stage biopharma focused on inhaled drug delivery, fell 20% Thursday. So what Here's a look at the key financial highlights from the first quarter: Revenue was $3 million. That figure included $1.8 million in bulk sales to a third party and $1.2 million in revenue from Afrezza sales to patients. Deferred revenue was $1.8 million at the end of the quarter. MannKind posted a net loss for the quarter of $16.3 million, or $0.17 per share. By contrast, Wall Street was expecting a net loss of only $0.09. Despite posting the big net loss, MannKind's cash balance
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind rises as FDA advances rare lung disease therapy to Phase 3 trial [Seeking Alpha]Seeking Alpha
- MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease [Yahoo! Finance]Yahoo! Finance
- MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseGlobeNewswire
- MannKind Repays Certain Debt Obligations [Yahoo! Finance]Yahoo! Finance
- MannKind Repays Certain Debt ObligationsGlobeNewswire
MNKD
Earnings
- 2/27/24 - Beat
MNKD
Sec Filings
- 4/22/24 - Form 3
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- MNKD's page on the SEC website